Integrated Diagnostics: Top Innovative Company in Biomedicine

Reading time: 2 – 3 minutes

Integrated Diagnostics is one of 10 biomedicine companies included in Technology Review’s 50 Most Innovative Companies (TR50) for 2012 [1].

Integrated Diagnostics

What is a TR50 company? It is a business whose innovations force other businesses to change their strategic course. TR50 companies are nominated by Technology Review’s editors who look for companies that, over the last year, have demonstrated original and valuable technology, are bringing that technology to market at a significant scale, and are clearly influencing their competitors.

Co-founded by Dr. Leroy Hood in 2009 to develop diagnostics and measurement technologies capable of monitoring hundreds of blood-based biomarkers simultaneously for earlier detection and more accurate management of complex diseases, Integrated Diagnostics takes a systems biology view of disease — one where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules. The company’s work is based on intellectual property developed by board members at the Institute of Systems Biology (ISB) and Caltech.

Integrated Diagnostics was chosen to be a TR50 company because they are enabling the monitoring of more disease markers by reducing the cost of diagnostic tests. A key innovation of the company is the development of synthetic antibodies to replace more expensive antibodies widely used in diagnostics.

Earlier this year, Integrated Diagnostics announced that they had entered into a strategic partnership with Agilent Technologies to develop protein-based tests that detect major human diseases at very early stages to improve treatment outcomes [2]. The partnership will develop high-throughput automated workflows that opens the possibility of screening for several hundred biomarkers in a single test.

Interested in other Top Innovative Companies in Biomedicine? Check them all out with the tag Top Innovative Companies in Healthcare.


  1. The 50 Most Innovative Companies in 2012. Technology Review. Accessed 2012 Apr 10.
  2. Agilent Technologies and Integrated Diagnostics Enter Strategic Partnership to Develop Protein-Based Assays for Early Disease Detection. Integrated Diagnostics. 2010 Jan 10.
About the Author

Walter Jessen, Ph.D. is a Data Scientist, Digital Biologist, and Knowledge Engineer. His primary focus is to build and support expert systems, including AI (artificial intelligence) and user-generated platforms, and to identify and develop methods to capture, organize, integrate, and make accessible company knowledge. His research interests include disease biology modeling and biomarker identification. He is also a Principal at Highlight Health Media, which publishes Highlight HEALTH, and lead writer at Highlight HEALTH.